Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen
Status:
Completed
Trial end date:
2018-05-23
Target enrollment:
Participant gender:
Summary
Primary Objective:
The purpose of this study was to determine the long term safety and tolerability of SAR245408
and SAR245409 as a monotherapy or as part of a combination regimen in participants who were
benefiting from treatment.